Folgen
Peter Hillmen
Peter Hillmen
Bestätigte E-Mail-Adresse bei leeds.ac.uk
Titel
Zitiert von
Zitiert von
Jahr
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National …
M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ...
Blood, The Journal of the American Society of Hematology 111 (12), 5446-5456, 2008
37192008
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
RR Furman, JP Sharman, SE Coutre, BD Cheson, JM Pagel, P Hillmen, ...
New England Journal of Medicine 370 (11), 997-1007, 2014
20032014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ...
New England Journal of Medicine 371 (3), 213-223, 2014
17382014
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease
RP Rother, L Bell, P Hillmen, MT Gladwin
Jama 293 (13), 1653-1662, 2005
16872005
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ...
New England Journal of Medicine 373 (25), 2425-2437, 2015
14472015
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
P Hillmen, NS Young, J Schubert, RA Brodsky, G Socié, P Muus, A Röth, ...
New England Journal of Medicine 355 (12), 1233-1243, 2006
12842006
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating, I Flinn, V Jain, JL Binet, P Hillmen, J Byrd, M Albitar, ...
Blood, The Journal of the American Society of Hematology 99 (10), 3554-3561, 2002
12202002
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ...
Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018
11532018
Natural history of paroxysmal nocturnal hemoglobinuria
P Hillmen, SM Lewis, M Bessler, L Luzzatto, JV Dacie
New England Journal of Medicine 333 (19), 1253-1258, 1995
10281995
Diagnosis and management of paroxysmal nocturnal hemoglobinuria
C Parker, M Omine, S Richards, J Nishimura, M Bessler, R Ware, ...
Blood 106 (12), 3699-3709, 2005
9982005
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D Catovsky, S Richards, E Matutes, D Oscier, MJS Dyer, RF Bezares, ...
The Lancet 370 (9583), 230-239, 2007
9022007
Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia
JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ...
New England Journal of Medicine 374 (4), 323-332, 2016
8832016
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ...
Annals of Oncology 32 (1), 23-33, 2021
8812021
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
P Hillmen, C Hall, JCW Marsh, M Elebute, MP Bombara, BE Petro, ...
New England Journal of Medicine 350 (6), 552-559, 2004
8132004
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
WG Wierda, TJ Kipps, J Mayer, S Stilgenbauer, CD Williams, A Hellmann, ...
Journal of Clinical Oncology 28 (10), 1749, 2010
7562010
Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia
JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ...
New England Journal of Medicine 378 (12), 1107-1120, 2018
7362018
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
P Hillmen, AB Skotnicki, T Robak, B Jaksic, A Dmoszynska, J Wu, ...
Journal of Clinical Oncology 25 (35), 5616-5623, 2007
7362007
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
AC Rawstron, FL Bennett, SJM O'Connor, M Kwok, JAL Fenton, ...
New England Journal of Medicine 359 (6), 575-583, 2008
7212008
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
RA Brodsky, NS Young, E Antonioli, AM Risitano, H Schrezenmeier, ...
Blood, The Journal of the American Society of Hematology 111 (4), 1840-1847, 2008
6492008
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
P Hillmen, P Muus, U Dührsen, AM Risitano, J Schubert, L Luzzatto, ...
Blood, The Journal of the American Society of Hematology 110 (12), 4123-4128, 2007
6422007
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20